What do systematic reviews say?

PUVA maintenance vs no maintenance

• Interventions for mycosis fungoides 2020 · Cochrane Headline outcomes only
  no estimate extracted
  1 study · 1 participants
  GRADE not reported

IFN‐α + PUVA vs PUVA

The review found no eligible studies for this question.

• Interventions for mycosis fungoides 2020 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Toric intraocular lens (IOL) vs limbal relaxing incisions (LRIs)

• Toric intraocular lens versus limbal relaxing incisions for corneal astigmatism after phacoemulsification 2019 · Cochrane Headline outcomes only
  no estimate extracted
  6 studies · 410 participants
  Very low

Irinotecan‐based regimens vs irinotecan

Irinotecan‐based regimens showed no clear difference in severe adverse effects compared with irinotecan (moderate certainty).

• Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  RR 1.18 [0.96, 1.45]
  6 studies · 2510 participants
  Moderate

Irinotecan + oxaliplatin vs irinotecan

Irinotecan + oxaliplatin probably leads to higher severe adverse effects compared with irinotecan (moderate certainty).

• Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  RR 1.22 [1.09, 1.37]
  1 study · 627 participants
  Moderate

Chemotherapy vs best supportive care

Chemotherapy probably leads to higher severe adverse effects compared with best supportive care (moderate certainty).

• Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  RR 1.19 [1.01, 1.4]
  1 study · 279 participants
  Moderate

FOLFIRI + targeted therapy vs FOLFIRI

FOLFIRI + targeted therapy probably leads to higher severe adverse effects compared with FOLFIRI (moderate certainty).

• Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  RR 1.3 [1.17, 1.45]
  6 studies · 3341 participants
  Moderate

FOLFOX + targeted therapy vs FOLFOX

FOLFOX + targeted therapy leads to higher severe adverse effects compared with FOLFOX (high certainty).

• Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  RR 1.2 [1.13, 1.28]
  2 studies · 1414 participants
  High

Irinotecan + targeted therapy vs irinotecan

Irinotecan + targeted therapy leads to higher severe adverse effects compared with irinotecan (high certainty).

• Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  RR 1.44 [1.31, 1.59]
  2 studies · 1704 participants
  High

Modern chemotherapy regimens vs 5‐flourouracil

Modern chemotherapy regimens probably leads to higher severe adverse effects compared with 5‐flourouracil (moderate certainty).

• Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  RR 1.39 [1.22, 1.58]
  3 studies · 843 participants
  Moderate

Bevacizumab plus chemotherapy vs chemotherapy alone

Chemotherapy + bevacizumab showed no clear difference in severe adverse effects compared with chemotherapy (low certainty).

• Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
  RR 1.07 [0.93, 1.25]
  4 studies · 1708 participants
  Low

Intervention not reported

• Lidocaine for reducing propofol‐induced pain on induction of anaesthesia in adults 2016 · Cochrane Headline outcomes only
  no estimate extracted
  32 studies · 4007 participants
  Low

Home (point‐of‐use) fortification of foods with multiple micronutrient powders vs multiple micronutrients (MMN)

• Multiple micronutrient powders for home (point‐of‐use) fortification of foods in pregnant women 2015 · Cochrane Headline outcomes only
  no estimate extracted
  0 participants
  GRADE not reported

Home (point‐of‐use) fortification of foods with multiple micronutrient powders vs iron folic acid (IFA)

• Multiple micronutrient powders for home (point‐of‐use) fortification of foods in pregnant women 2015 · Cochrane Headline outcomes only
  no estimate extracted
  0 participants
  GRADE not reported

INFORMATION AND COMMUNICATION TECHNOLOGY (ICT) FOR PROMPTING/SUPPORT + STANDARD CARE vs usual care

• Information and communication technology based prompting for treatment compliance for people with serious mental illness 2014 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Perioperative statins vs placebo or no treatment

• Perioperative statin therapy for improving outcomes during and after noncardiac vascular surgery 2013 · Cochrane Headline outcomes only
  no estimate extracted
  3 studies · 188 participants
  GRADE not reported

Preventive interventions vs no preventive interventions

• Preventive interventions for postnatal psychosis 2013 · Cochrane Headline outcomes only
  no estimate extracted
  0 studies · 0 participants
  GRADE not reported

Systemic tranexamic acid vs control

The review found no eligible studies for this question.

• Medical interventions for traumatic hyphema 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found

Case management for integrated care vs usual care of older people living with frailty

• Case management for integrated care of older people with frailty in community settings 2023 · Cochrane Headline outcomes only
  no estimate extracted
  2 studies · 592 participants
  Low

Vestibular rehabilitation vs no treatment

The review found no eligible studies for this question.

• Non‐pharmacological interventions for prophylaxis of vestibular migraine 2023 · Cochrane Headline outcomes only
  no estimate extracted
  Studies not reported
  No studies found